CSL Limited
https://www.csl.com/
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Latest From CSL Limited
INTERACT Meeting Timing Remains Point Of Confusion
US FDA review divisions will determine whether the meeting is appropriate because there are no one-size-fits-all requirements.
Dizal Scores First JAK1 Approval For Advanced PTCL
China's Dizal has won the first approval worldwide, in its home market, for a JAK1 inhibitor in relapsed/refractory peripheral T-cell lymphoma (PTCL), based on a pivotal Phase II trial. The biotech is also planning a Phase III study with the molecule for second-line PTCL.
Stock Watch: Thoroughly Moderna Missteps
When life hands a biotech company the equivalent of good grapes, the expectations are for its products to be the equivalent of fine wine. Before that Moderna looks likely to make lemonade.
Sarepta Retains DMD Gene Therapy Lead As Pfizer Stumbles
Pfizer’s Phase III CIFFREO study in DMD failed to meet primary and key secondary endpoints, likely removes it as a potential competitor to Sarepta’s Elevidys.
Company Information
- Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Medical Devices
- Diagnostic Equipment & Supplies
-
Diagnostic Imaging Equipment & Supplies
- Digital Imaging
- Other Names / Subsidiaries
-
- bioCSL
- CSL Behring
- CSL Behring Mexico
- CSL Biotherapies
- CSL Bioplasma
- Seqirus
- Wuhan Zhong Yuan Rui De Biological Products
- Ruide
- Calimmune, Inc.
- Vitaeris Inc.
- Zenyth Therapeutics Ltd.
- CSL, Ltd.
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Email Company
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice